Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

14.45 -0.19 (-1.26%)
Streaming Delayed Price Updated: 10:48 AM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
News headline image
Clorox, Crocs And Some Other Big Stocks Moving Lower On Thursday ↗
  AMTD Digital Inc. (NYSE: HKD) dipped 43.6% to $620.00 on possible profit taking after the stock surged over the last few trading days. 
Via Benzinga
News headline image
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned ↗
Intellia is backing off the higher dose of a gene-editing drug in cardiomyopathy patients. 
Via Investor's Business Daily
News headline image
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Recap: Intellia Therapeutics Q2 Earnings ↗
  Intellia Therapeutics (NASDAQ:NTLA) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis ↗
 
Via Benzinga
News headline image
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today? ↗
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran. 
Via InvestorPlace
News headline image
7 Cathie Wood Stocks Trading at a Discount Right Now ↗
These 7 Cathie Wood stocks are the best choices to buy in June. COIN, FATE, NTLA, MELI, TDOC, TSLA, and ZM can make excellent investments. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
The 3 Leaders of the Gene Editing Revolution ↗
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
Via InvestorPlace
News headline image
BMO Initiates Coverage On This Gene Editing Spearhead ↗
 
Via Benzinga
News headline image
4 Analysts Have This to Say About Intellia Therapeutics ↗
Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:NTLA) within the last quarter: 
Via Benzinga
News headline image
7 Moonshot Investments Upending a $10 Trillion Industry ↗
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
News headline image
Do You Have Biotech FOMO? It Might Be Time To Pay Attention To These Names ↗
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
News headline image
Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying ↗
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
News headline image
Analyst Ratings for Intellia Therapeutics ↗
Over the past 3 months, 7 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Analyst Ratings for Intellia Therapeutics ↗
Over the past 3 months, 8 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading. 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Earnings Preview For Intellia Therapeutics ↗
Intellia Therapeutics (NASDAQ:NTLA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
How To Attend Intellia Therapeutics Q1 2022 Earnings Conference Call ↗
Intellia Therapeutics (NASDAQ:NTLA) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗
 
Via Benzinga
News headline image
Good Entry Point for Biotech Stocks ↗
Life science and biotech stocks had a good week with the most well-known ETFs up 3-4% for the week and off recent bottoms. 
Via Talk Markets
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
On Thursday, 236 companies hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
News headline image
FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials ↗
The FDA has outlined new draft guidance on what should be submitted in a clinical trial application and potentially concerning safety issues to track the genome editing products. 
Via Benzinga
News headline image
Here's How Much $100 Invested In Intellia Therapeutics 5 Years Ago Would Be Worth Today ↗
Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 19.59% on an annualized basis. Buying $100 In NTLA: 5 years ago, an investor could have... 
Via Benzinga
News headline image
Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer ↗
Intellia Therapeutics Inc's (NASDAQ: NTLA) CRISPR-powered T cell therapy has received an FDA orphan drug designation. The autologous T cell receptor therapy, dubbed... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2022 ↗
Upgrades According to Brookline Capital, the prior rating for Intellia Therapeutics Inc (NASDAQ:NTLA) was changed from Hold to Buy. In the fourth quarter, Intellia Therapeutics... 
Via Benzinga
News headline image
63 Biggest Movers From Yesterday ↗
Gainers Indonesia Energy Corporation Limited (NASDAQ: INDO) shares climbed 39.3% to close at $20.20 on Thursday after jumping around 35% on Wednesday. DBV Technologies S.A. (... 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.